J&J Topamax Approved For Migraine Prevention In Twice-Daily Dose
This article was originally published in The Pink Sheet Daily
Executive Summary
The supplemental indication for topiramate clears FDA. The recommended twice-daily dose for migraine prevention may place Topamax at a disadvantage to Abbott’s once-daily dosing for Depakote ER.You may also be interested in...
Topamax Launch For Migraine Prevention Includes Unbranded DTC Ad
Topamax Launch For Migraine Prevention Includes Unbranded DTC Ad
J&J Is Spitzer's Next Target: New York AG Opens Broad Off-Label Promotion Investigation
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: